Current and future opportunities for liquid biopsy of circulating biomarkers to aid in early cancer detection

Abstract

Early diagnosis of cancer can significantly improve treatment and survival outcomes. Imaging and tissue biopsy are the gold standard diagnostic approaches but are costly, invasive, and often unable to detect early-stage tumors. The past decade has marked an acceleration in the discovery and development of liquid biopsy tests for aiding in the detection of various types of tumor markers in non-tissue samples, such as blood. Liquid biopsy markers include circulating tumor cells, as well as tumor cell fragments, nucleic acids, and proteins. Liquid biopsy may be useful in screening patients considered to be at high risk of developing cancer, for refining diagnosis when combined with other test results, and for early detection of recurrence. Advances in big data analytics, informatics, and artificial intelligence will make it possible to combine patient history, clinical data, and liquid biopsy marker profiles to achieve more accurate and earlier diagnosis. In this review, we summarize the current use of liquid biopsy in cancer care, including the development of multi-analyte panels to improve diagnostic accuracy and detect several cancer types in a single assay. We highlight recent advances for potential future applications of liquid biopsy to aid in the diagnosis of early-stage lung cancer. We also discuss the opportunities and challenges of integrating liquid biopsy into current algorithms for cancer screening and diagnosis.

Keywords

Cancer early detection / diagnostic algorithm / biomarkers / blood / serum / analyte

References

[1] American Cancer Society. Lifetime risk of developing or dying from cancer. 2020; Available from: https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html. [Last accessed on 29 June 2022].

[2] Miller KD,Mariotto AB.Cancer treatment and survivorship statistics, 2019.CA Cancer J Clin2019;69:363-85

[3] Palmirotta R,Cafforio P.Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology.Ther Adv Med Oncol2018;10:1758835918794630 PMCID:PMC6116068

[4] Morgan TM.Liquid biopsy: Where did it come from, what is it, and where is it going?.Investig Clin Urol2019;60:139-41 PMCID:PMC6495043

[5] Rossi G.Promises and pitfalls of using liquid biopsy for precision medicine.Cancer Res2019;79:2798-804

[6] Casanova-Salas I,Boutros PC.Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer.Eur Urol2021;79:762-71 PMCID:PMC8941682

[7] Domínguez-Vigil IG,Wang JY,Barrera-Saldaña HA.The dawn of the liquid biopsy in the fight against cancer.Oncotarget2018;9:2912-22 PMCID:PMC5788692

[8] Li D,Fan D.Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies.Am J Physiol Cell Physiol2021;321:C779-97

[9] Werner S,Pantel K.Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies.Mol Aspects Med2020;72:100817

[10] Clarke-Pearson DL.Clinical practice. Screening for ovarian cancer.N Engl J Med2009;361:170-7

[11] Lennon AM. Diagnostic and therapeutic response markers, Pancreatic Cancer. New York, NY: Springer, 2010; pp. 675-701.

[12] Locker GY,Harris J.ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.J Clin Oncol2006;24:5313-27

[13] Bhardwaj M,Werner S,Brenner H.Blood-based protein signatures for early detection of colorectal cancer: a systematic review.Clin Transl Gastroenterol2017;8:e128 PMCID:PMC5717517

[14] Yang D,Powell CA.Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study.Cancer2018;124:262-70

[15] Hsu T,Gould B.Abstract PO-007: plasma-based detection of pancreatic cancer: A multiomics approach.Cancer Res2021;81:PO-007

[16] Cai Z,He Y.Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.ESMO Open2021;6:100021 PMCID:PMC7841321

[17] Guo D,Wang Y.956P A multi-analyte liquid biopsy assay integrating cfDNA methylation and protein biomarkers for liver cancer diagnosis.Ann Oncol2021;32:S828

[18] Sozzi G,Mariani L.Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients.Cancer Res2001;61:4675-78

[19] Wroclawski ML,Fonseca FL.Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients.Tumour Biol2013;34:2921-7

[20] Cohen JD,Wang Y.Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science2018;359:926-30 PMCID:PMC6080308

[21] Pinsky PF,Kramer BS.Prostate cancer screening - a perspective on the current state of the evidence.N Engl J Med2017;376:1285-9

[22] Kleif J,Davis GJ,Nielsen HJ.898 Development of blood-based, cancer-associated biomarkers for early detection of colorectal cancer: significant differences between results from symptomatic and screening subjects.Gastroenterology2020;158:S-1538

[23] Wen YH,Hsu CM,Chiu CT.Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: results from a 12-year experience.Clin Chim Acta2015;450:273-6

[24] Chung S.False-positive elevations in carcinoembryonic antigen levels at a health screening center.Lab Med Online2019;9:146

[25] Wang HY,Wen CN,Chen CH.Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers.PLoS One2016;11:e0158285 PMCID:PMC4927114

[26] Wang HY,Shi S.Improving multi-tumor biomarker health check-up tests with machine learning algorithms.Cancers (Basel)2020;12:1442 PMCID:PMC7352838

[27] National Cancer Institute. Tumor markers in common use. Available from: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list [Last accessed on 29 June 2022].

[28] Duffy MJ,Crown J.Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA.Tumour Biol2018;40:1010428318776169

[29] Seijo LM,Ajona D.Biomarkers in lung cancer screening: achievements, promises, and challenges.J Thorac Oncol2019;14:343-57 PMCID:PMC6494979

[30] Cargnin S,Genazzani AA.Quantitative analysis of circulating cell-free DNA for correlation with lung cancer survival: a systematic review and meta-analysis.J Thorac Oncol2017;12:43-53

[31] Qvick A,Carlsson J,Karlsson C.Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.Mol Med2021;27:68 PMCID:PMC8254966

[32] Tissot C,Villar S.Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.Eur Respir J2015;46:1773-80

[33] González de Aledo-Castillo JM,Soler-Perromat A.Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients.Eur J Nucl Med Mol Imaging2021;48:3631-42

[34] Chaudhuri AA,Lovejoy AF.Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.Cancer Discov2017;7:1394-403 PMCID:PMC5895851

[35] Phallen J,Woodward BD.Early noninvasive detection of response to targeted therapy in non-small cell lung cancer.Cancer Res2019;79:1204-13 PMCID:PMC6481620

[36] Sestini S,Marchiano A.Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.Oncotarget2015;6:32868-77 PMCID:PMC4741735

[37] Liu MC.Transforming the landscape of early cancer detection using blood tests-Commentary on current methodologies and future prospects.Br J Cancer2021;124:1475-7 PMCID:PMC8076196

[38] Duffy MJ,Crown J.Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?.Clin Chem Lab Med2021;59:1353-61

[39] Lennon AM,Kinde I.Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.Science2020;369:eabb9601 PMCID:PMC7509949

[40] Liu MC,Klein EA.Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.Ann Oncol2020;31:745-59 PMCID:PMC8274402

[41] Wan N,Liu TY.Machine learning enables detection of early-stage colorectal cancer by whole-genome sequencing of plasma cell-free DNA.BMC Cancer2019;19:832 PMCID:PMC6708173

[42] Lin J,Dzamba M.Evaluation of a sensitive blood test for the detection of colorectal advanced adenomas in a prospective cohort using a multiomics approach.JCO2021;39:43-43

[43] Ulz P,Zhou Q.Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.Nat Commun2019;10:4666 PMCID:PMC6789008

[44] Putcha G,Skates S.Multicancer screening: one size does not fit all.JCO Precis Oncol2021;5:574-6

[45] Holdenrieder S,Morgenstern D.Clinically meaningful use of blood tumor markers in oncology.Biomed Res Int2016;2016:9795269 PMCID:PMC5155072

[46] McKeegan EM,Davis G.Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.Lung Cancer2015;90:296-301

[47] Rifai N. Tietz textbook of clinical chemistry and molecular diagnostics, 6th ed. St. Louis, MO: Saunders, 2017; Available from: https://www.us.elsevierhealth.com/tietz-textbook-of-clinical-chemistry-and-molecular-diagnostics-9780323359214.html [Last accessed on 29 June 2022].

[48] Lamb YN.Epi proColon((R)) 2.0 CE: a blood-based screening test for colorectal cancer.Mol Diagn Ther2017;21:225-32

[49] Imperiale TF,Itzkowitz SH.Multitarget stool DNA testing for colorectal-cancer screening.N Engl J Med2014;370:1287-97

[50] Guler GD,Ku CJ.Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA.Nat Commun2020;11:5270 PMCID:PMC7572413

[51] Macdonald IK,Chapman CJ.Autoantibodies: opportunities for early cancer detection.Trends Cancer2017;3:198-213

[52] Hemken PM,Yang X.Validation of a novel model for the early detection of hepatocellular carcinoma.Clin Proteomics2019;16:2 PMCID:PMC6334458

[53] Yang JD,Mara KC.GALAD Score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score.Cancer Epidemiol Biomarkers Prev2019;28:531-8 PMCID:PMC6401221

[54] Yang T,Wang G.A Novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B.Clin Chem2019;65:1543-53